INNOCARE (688428.SH): Apremilast treatment for systemic lupus erythematosus reaches Phase IIb study primary endpoint.
Nuo Cheng Jian Hua (688428.SH) announced that the Phase IIb clinical study of the company's independently developed BTK inhibitor, obutinib, for the treatment of systemic lupus erythematosus (SLE) has reached its primary endpoint, and has been approved by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) to conduct Phase III clinical trials. The company will soon initiate the clinical study.
INNOCARE (688428.SH) announced that the Phase IIb clinical study of the company's independently developed BTK inhibitor, obutinib, for the treatment of systemic lupus erythematosus (SLE) has achieved its main endpoint, and has received approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) to conduct a Phase III clinical trial. The company will soon initiate this clinical study.
The Phase IIb results show that after 48 weeks of treatment, obutinib demonstrated excellent efficacy, good tolerability, and safety in patients.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
